Equinox is lighting up in one of the hottest REE districts on the planet
Equinox Resources is accelerating exploration and drill campaigns across its recently staked Campo Grande and Mata da Corda REE projects in Brazil Exceptional REE grades [more…]
Straker to benefit as global economic pressures drive demand for AI translation
Valuations for private companies like DeepL and Keywords Studios are soaring as demand for cost-effective translation solutions increases. ASX-listed Straker is leveraging AI to make [more…]
TG6 Metals’ David Selfe lights up hard rock lithium and the case for Lake Johnston
Geologist David Selfe says ‘size, grade and depth’ important for hard rock lithium deposits WA’s own hard rock lithium scene has a new emerging district [more…]
Broking Bad: A promise of more expensive tech spend leaves brokers strongly divided over ASX
Late last week the ASX Ltd (ASX:ASX) hosted its big investor day, which aimed to provide some clarity on the local bourse operator’s epic telegraphing [more…]
MoneyTalks: Broker has big price target on circular economy-focused company, Close the Loop
Canaccord slaps Close the Loop with target price of 65c, well above current price CLG recycles print cartridges and is innovating sustainable packaging The broker [more…]
Stockhead
The post Stockhead appeared first on Stockhead.
Break it Down: Iltani Resources’ world-class silver-indium discovery steps out and up
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Iltani Resources’ [more…]
Monsters of Rock: Rio’s Serbian lithium gamble could be back on
Rio Tinto has been given hope the Serbian Government will back its Jadar lithium mine in the face of opposition from community and environment groups [more…]
Closing Bell: Tech, Energy weigh down ASX; Schrole up almost 200pc on acquisition deal
Aussie stocks start the week flat; energy and tech sectors lead declines Investor caution prevails ahead of RBA rates decision Chinese Premier Li Qiang meets [more…]
Neurotech’s autism treatment reaches two-year trial milestone
Neurotech International says ASD patients in its Phase 1/2 trial of NTI164 have now been on treatment for more than two years Initial positive [more…]
